tbuckley/cabot-search huggingface dataset:
Studies in Carcinogenesis XIV. 3-Substituted and 10-Substituted Derivatives of 1,2-Benzanthracene&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: M. J. Shear, Joseph Leiter, Adrien Perrault
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article Studies in Carcinogenesis XIV. 3-Substituted and 10-Substituted Derivatives of 1,2-Benzanthracene Get access M. J. Shear, M. J. Shear principal biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph Leiter, Joseph Leiter junior chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Adrien Perrault Adrien Perrault assistance Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 3, December 1940, Pages 303–336, https://doi.org/10.1093/jnci/1.3.303 Published: 01 December 1940
Abstract 18417: Does Active Participation in Cardiac Rehabilitation Adversely or Favorably Affect BNP Levels in Post-Acute Myocardial Infarction Patients With Already Elevated Baseline BNP ?
Authors: Ayumi Date, Tatsuo Tokeshi, Reon Kumasaka, Kazuhiro Nakao, Tetsuo Arakawa, Shigefumi Fukui, Takuya Hasegawa, Michio Nakanishi, Masanobu Yanase, Teruo Noguchi, Satoshi Yasuda, Hisao Ogawa, Yoichi Goto
Journal: Circulation (2016)

Background:  In post-acute myocardial infarction (AMI) patients, exercise-based cardiac rehabilitation (CR) has been reported to counteract left ventricular (LV) remodeling. However, in post-AMI patients with elevated B-type natriuretic peptide (BNP) levels at baseline, it is unclear whether active participation in CR leads to a decrease or further elevation of BNP levels. Accordingly, we studied determinants of sustained elevation of BNP in post-AMI patients with high baseline BNP levels.   Methods:  We studied 293 consecutive AMI patients who had a high baseline BNP level (>=200pg/ml) and participated in our 3-month CR program. All patients underwent blood sampling and symptom-limited cardiopulmonary exercise testing (measurements for peak oxygen uptake [PVO2]) at the beginning and the end of the CR. Patients were divided into two groups according to the percent of changes in BNP levels (%ΔBNP) from the beginning to 3-month: Decreased (Dec) group (%ΔBNP =-10%, n=33).   Results:  At baseline, Sus group, compared with Dec group, had higher prevalence of Killip classification>=2 (Sus 37 vs Dec 20%, P=0.04), lower LV ejection fraction (LVEF, 35±10 vs 41±10%, P=0.003) and larger LV systolic diameter (41±11 vs 38±8mm, P=0.04), whereas baseline PVO2 (17.9±3.8 vs 18.7±3.6ml/kg/min, NS) was similar. During CR, Sus group had lower training heart rate (TrHR, 93±14 vs 100±14bpm, P=0.03) than Dec group, while the number of ambulatory CR session attendance (14.7±8.1 vs 13.4±9.1, NS) was similar. After 3-month CR, BNP decreased in the whole patients, but it was significantly higher in Sus group than in Dec group (375 vs 133pg/mL, P   Conclusion:  In AMI patients with elevated BNP at baseline, lower LVEF, lower TrHR and lower improvement in PVO2 may predict sustained BNP elevation after CR. This result in turn suggests that active CR participation at a higher TrHR and a greater PVO2 improvement may be associated with a greater fall in initially elevated BNP.
Women still not being told about pregnancy risks of valproate
Authors: Jacqui Wise
Journal: BMJ (2017)

Two thirds of women who take the antiepileptic drug sodium valproate said they had not received new safety warnings about the dangers of taking it during pregnancy, a survey carried out by epilepsy charities has found. A similar survey last year found that half of women taking the drug were unaware it could harm their fetus.1

The new results are to be presented at a public hearing on the safety of valproate drugs organised by the European Medicines Agency on 26 September in London. This is the first time that the EMA has held a public hearing as part of the safety review of a drug, and it will …
Prenatal Exposure to Perfluoroalkyl Substances and Cardiometabolic Risk in Children from the Spanish INMA Birth Cohort Study
Authors: Cyntia B. Manzano-Salgado, Maribel Casas, Maria-Jose Lopez-Espinosa, Ferran Ballester, Carmen Iñiguez, David Martinez, Dora Romaguera, Silvia Fernández-Barrés, Loreto Santa-Marina, Mikel Basterretxea, Thomas Schettgen, Damaskini Valvi, Jesus Vioque, Jordi Sunyer, Martine Vrijheid
Journal: Environmental Health Perspectives (2017)

Background: Perfluoroalkyl substances (PFAS) may affect body mass index (BMI) and other components of cardiometabolic (CM) risk during childhood, but evidence is scarce and inconsistent. Objectives: We estimated associations between prenatal PFAS exposures and outcomes relevant to cardiometabolic risk, including a composite CM-risk score. Methods: We measured perfluorohexanesulfonic acid (PFHxS), perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) in maternal plasma (first trimester). We assessed weight gain from birth until 6 mo. At 4 and 7 y, we calculated the age- and sex-specific z-scores for BMI, waist circumference (WC), and blood pressure (BP) (n≈1,000). At age 4, we calculated the age-, sex-, and region-specific z-scores for cholesterol, triglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627). At age 4, we calculated a CM-risk score (n=386) as the sum of the individual age-, sex-, and region-specific z-scores for WC, BP, HDL-C, and TGs. We used the average between the negative of HDL-C z-score and TGs z-score to give similar weight to lipids and the other components in the score. A higher score indicates a higher cardiometabolic risk at age 4. Results: PFOS and PFOA were the most abundant PFAS (geometric mean: 5.80 and 2.32 ng/mL, respectively). In general, prenatal PFAS concentrations were not associated with individual outcomes or the combined CM-risk score. Exceptions were positive associations between prenatal PFHxS and TGs z-score [for a doubling of exposure, β=0.11; 95% confidence interval (CI): 0.01, 0.21], and between PFNA and the CM-risk score (β=0.60; 95% CI: 0.04, 1.16). There was not clear or consistent evidence of modification by sex. Conclusions: We observed little or no evidence of associations between low prenatal PFAS exposures and outcomes related to cardiometabolic risk in a cohort of Spanish children followed from birth until 7 y. https://doi.org/10.1289/EHP1330
Short tandem repeat genotyping using identifilerTM is a reproducible and cost-effective method for establishing and monitoring identity of pediatric cancer cell lines
Authors: Daniel Cabral, Heather Feaman, Michael Sheard, C. Reynolds
Journal: Cancer Research (2007)

403   Cell line identity is reportedly mistaken in an alarmingly high percentage of cases (16-30%). Short tandem repeat (STR) genotyping (microsatellite DNA fingerprinting) is the standard in forensics, theoretically providing unique profiles for every person on the planet. However, inherent genetic instability and/or selective pressures can sometimes cause slight alterations to STR profiles of cell lines, perhaps inhibiting wider use of the method in cancer research. We genotyped a large panel of pediatric cancer cell lines to assess the utility of STRs in identifying cell cultures and to determine when and to what degree microsatellite alterations (MSA) typically occur. We monitored costs and the occurrence of mistaken cell line identity to address the feasibility and necessity of the method. Polymerase chain reaction with the Applied Biosystems Ampf l STR TM  Identifiler TM  kit (16 loci amplified) was performed to obtain STR profiles for 124 cell lines we established and 51 lines from other investigators (175 total): 102 neuroblastoma (NB), 30 leukemia or lymphoma, 10 retinoblastoma, 10 Ewing’s family tumor (ESFT), 8 rhabdomyosarcoma, 5 brain tumor, 5 carcinoma, 1 prostate, and 4 EBV-transformed lymphoblastoid cell lines. We genotyped 525 total samples, including patient material. Comparison to patient tissue or cell lines from the same patient with separate establishment dates verified identity of 57 lines. All other lines showed unique profiles. Cell lines showed 1-3 MSA compared to blood cells from the same patients in 5 of 12 NB and 1 leukemia. We found no variation between cell lines established from different anatomic sites in the same patient at the same time in 5 NB and 1 rhabdomyosarcoma. Cell lines established after therapy and/or progression of disease showed MSA compared to lines established at diagnosis from the same patients in 5 of 8 NB, 1 leukemia, and 1 ESFT. Leukemia and ESFT lines showed greater MSA than NB lines. We also compared cell line profiles before and after in vitro manipulations. Two of 3 NB cell lines showed 1-2 MSA after selection for resistance to retinoic acid. Two of 5 NB lines showed 1-2 MSA after retroviral transfection and marker selection. Two of 4 NB lines showed 3 MSA in relation to corresponding EBV-transformed lymphoblastoid lines. Of 65 cell lines with 2 or more samples at different passages in vitro, 21 showed MSA in at least 1 sample; several lines showed high MSA. Despite MSA, unambiguous identification was achieved in all 525 samples. Cell line identity was mistaken in 9% of samples (36 cross-contaminated/mislabeled, 12 mixtures). Profiles of mixtures were composites of two known cell line profiles in all cases and were distinguishable from lines with high MSA. Genotyping with Identifiler TM  costs ~$30/sample. In conclusion, Identifiler TM  can be feasibly used to reliably prevent artifacts of misidentification.
The WPA Action Plan 2017‐2020
Authors: Helen Herrman
Journal: World Psychiatry (2017)

The WPA Action Plan 2017-2020 sets out a strategy for expanding the contribution of psychiatry to improved mental health for people across the globe. It is based on consultation within the WPA and with potential partner organizations as well as on the work that has preceded it. It builds on the strong capacity of the WPA to promote mental health and improve equitable access and quality of mental health care. In doing so, the plan provides a targeted strategy for reaching people, particularly young people, who face adversity and disadvantage. Three characteristics frame the strategic intent of the Action Plan: continuation of WPA's contribution to developing the profession of psychiatry; development of operational work that focuses on critical mental health topics; attraction of new investment to support this work. In focusing on specific population groups, the plan calls attention to the needs and strengths of children and young people, who are prominent in each of the groups identified. Mental health promotion as well as prevention and treatment of mental illness are all incorporated into the plan. Three types of actions are anticipated. The first is support for sharing of best practice. The second is building capacity for the profession to work effectively in specific settings of disadvantage. The third is encouraging psychiatrists and other health professionals to use their expertise in facilitating the mental health work of non-specialists across a range of community settings. In order to achieve its aims, the WPA will mobilize the professionals, knowledge and resources available to the Association. We will encourage the participation of Member Societies and individual psychiatrists in the themes and activities described. Many organizations have been working for extended periods of time to address the global mental health needs that also concern us. Working together in a clear and strategic manner will allow us to serve vulnerable populations globally in a better way. The activities set forward by this Action Plan are designed to be attractive to new funders and investors. They provide opportunities to have an impact on needs that are priorities for human and social development globally. Helen Herrman President Elect, World Psychiatric Association The author acknowledges support of S. Fisher and M.V. Rodrigues of Community Works in the development of the Action Plan.
Intraoperative radiotherapy as a boost after neoadjuvant chemotherapy: DFS after a median follow-up of 4 years.
Authors: Hans-Christian Kolberg, Gyoergy Loevey, Leyla Akpolat-Basci, Miltiades Stephanou, Michael Untch
Journal: Journal of Clinical Oncology (2015)

e12050 Background: The expected local recurrence rate in 5 year follow-up after breast conserving therapy and whole breast irradiation is 7,6%. Adding a boost of the index region results in a reduced recurrence rate of 4,3%. The boost irradiation as an intraoperative procedure showed a further decrease of local recurrence rates down to 1,75% . We adapted this approach to patients after neoadjuvant chemotherapy (NACT) and are reporting the DFS after a median of 4 years of follow up. To our knowledge this is the first time that data concerning intraoperative radiotherapy after neoadjuvant chemotherapy are presented. Methods: Between April 2010 and November 2011 we treated 61 patients after NACT (+/- Trastuzumab according to HER2-status) with an intraoperative boost of 20 Gy with a 50 kV X-ray source followed by an external radiation with 50 Gy. The patient characteristics were as follows and represent the high risk cohort typical for a cohort of patients treated with NACT: median age 54,9 years, 24 pts premenopausal / 37 pts postmenopausal, 31 pts G2 / 30 pts G3, 39 pts ER positive / 22 pts ER negative, 29 pts PR positive / 32 pts PR negative, 24 pts HER2 positive / 37 pts HER2 negative, 36 pts T1 / 24 pts T2 / 1 pt T3, 28 pts node negative / 33 pts node positive. 19 patients reached a pCR. 17 patients needed more than one operation. No patient was lost to follow up and at the time of data closure the median follow up was 49,56 months. Results: At a median follow up of 49,56 months the DFS was 86,89%, the DDFS 93,44%. 18 of the 19 patients were disease free in the group of patients who reached a pCR (DFS 94,74%). In the group of 42 patients who had residual tumor after NACT, 35 were disease free (DFS 83,33%). Conclusions: A DFS of 86,89% compares favorably to the DFS expected for patients after NACT. The higher DFS in the pCR-group was expected due to the fact that a pCR after NACT +/- Trastuzumab is predictive for DFS. Still the DFS in the non pCR-group compares favorably to the known data for patients not reaching a pCR. Our data are the first on IORT as a boost after neoadjuvant chemotherapy and show a favorable outcome of the patients in this high risk group. They strongly encourage the design of prospective trials in this indication.
Correlation analysis between the chemical contents and bioactivity for the quality control of Alismatis Rhizoma
Authors: Xiaoxv Gao, Chengpeng Sun, Zhenglong Yu, Jian Cang, Xiangge Tian, Xiaokui Huo, Lei Feng, Xinguang Liu, Chao Wang, Baojing Zhang, Xiaochi Ma
Journal: Acta Pharmaceutica Sinica B (2017)

In order to clarify regions of production and to discriminate processing methods, quantitative and qualitative analyses for saccharides and terpenes in 35 batches of Alismatis Rhizoma were performed. Methodologies included HPLCPDA, HPLCVWD and UHPLCMSn, combined with principal component analysis (PCA) and partial least squares regression techniques (PLSR). The inhibitory effects of triterpenes and Alismatis Rhizoma extracts on lipase activity were evaluated in vitro. PLSR analysis revealed significant positive correlations (R2 = 0.5795) between the contents of triterpenes 10, 14, 15, 18 and 22 and the inhibitory effects of Alismatis Rhizoma. The present study establishes an effective method for simultaneous determination of multiple components, and identifies key bioactive triterpenes. These results can be used for systematic and novel analytical strategies for the quality control of Alismatis Rhizoma production.
Frequency of EGFR mutations in peruvian patients with non-small cell lung cancer.
Authors: Juan C Gomez de la Torre, Angelo Storace, Christian Piscocha, Jose Landa, Carlos Roe, Eduardo Roe, Claudia Barletta, Luis Mas
Journal: Journal of Clinical Oncology (2015)

e22063 Background: Determination of mutational status of the EGFR gene is important for the adequate choice of targeted therapy with EGFR tyrosine kinase inhibitors (TKI´s) in NSCLC patients. In this study we describe the frequency of EGFR mutations in a large cohort of Peruvian patients. Methods: We evaluated tumor samples from 398 metastatic NSCLC patients tested for known EGFR mutations in exon 18 (G719X), exon 19 (deletions), exon 20 (T790M, S768I and insertions) and exon 21 (L858R). Samples were from a mutational testing program sponsored by a pharmaceutical company. All samples were processed at a central reference laboratory. Results: Fifty five percent of patients were male. Frequency of EGFR mutation was 36.7% (n = 146). Mutation G719X (exon 18) was present in 1% (n = 4) of cases; deletions in exon 19 were present in 19.6% (n = 78) of cases. Mutations in exon 20 had a frequency of 3.5% (n = 14), from which, 8 cases had insertions, 5 cases had the mutation T790M and 1 case had the mutation S768I. Mutation L858R (exon 21) in 14.1% (n = 56) of cases. Coexistence of two mutations were present in exon 19/exon 20 (n = 3) and exon 20/ exon 21 (n = 3). There was an association between gender and EGFR status and female patients were more likely to have any EGFR mutation (P < 0.001, Relative Risk = 1.92). In all cases with EGFR mutated, 138 (94.5%) cases had a sensible profile for EGFR TKI´s while 8 cases (5.5%) had mutations associated with resistance to TKI´s. Conclusions: Frequency of EGFR mutation in the Peruvian population show similar pattern to reported for other Latin American countries. Mutations in exon 19 are the most frequent.
Seven tips for developing and maintaining a high performance sports medicine team
Authors: Tim J Gabbett, Simon Kearney, Leslie J Bisson, Joe Collins, Robby Sikka, Nathan Winder, Craig Sedgwick, Ed Hollis, Jeremy M Bettle
Journal: British Journal of Sports Medicine (2017)

In 1989, Stephen Covey published his highly acclaimed book ‘ The 7 Habits of Highly Effective People ’.1 This book, with sales exceeding 25 million copies, describes how individuals contribute to successful organisations, in part by fostering interdependence among staff. The multidisciplinary2 and interdependent3 nature of high-performance sporting teams have been highlighted in BJSM editorials. Central in these commentaries has been the importance of collective decision-making and shared responsibilities.2 With sports medicine teams growing rapidly, sport has become somewhat of an ‘arms race’, with team owners often convinced that the secret to developing a winning franchise lies in the quality of the backroom staff. When assembling a sports medicine team to support the coaches and athletes, what should owners be looking for? What are the characteristics of a highly effective sports medicine team? Here, we provide a perspective from 12 different high-performance organisations based in four countries.

‘Doing the 1%-ers’ is a phrase used ad nauseam in sport. However, it takes a lot of ‘1%-ers’ to make 100%! The foundations of successful performance and injury prevention are based on a well-designed and implemented training programme …
SAMHD1 Sheds Moonlight on DNA Double-Strand Break Repair
Authors: Maria Jose Cabello-Lobato, Siyue Wang, Christine Katrin Schmidt
Journal: Trends in Genetics (2017)

SAMHD1 (sterile α motif and histidine (H) aspartate (D) domain-containing protein 1) is known for its antiviral activity of hydrolysing deoxynucleotides required for virus replication. Daddacha et al. identify a hydrolase-independent, moonlighting function of SAMHD1 that facilitates homologous recombination of DNA double-strand breaks (DSBs) by promoting recruitment of C-terminal binding protein interacting protein (CTIP), a DNA-end resection factor, to damaged DNA. These findings could benefit anticancer treatment.
Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When is the Most Clinically Relevant Time to Evaluate?—Reply
Authors: Selcuk Adabag, Kristen K. Patton, Alfred E. Buxton
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Exercise and pregnancy in recreational and elite athletes: 2016/17 evidence summary from the IOC expert group meeting, Lausanne. Part 4—Recommendations for future research
Authors: Kari Bø, Raul Artal, Ruben Barakat, Wendy J Brown, Gregory A L Davies, Mike Dooley, Kelly R Evenson, Lene A H Haakstad, Bengt Kayser, Tarja I Kinnunen, Karin Larsén, Michelle F Mottola, Ingrid Nygaard, Mireille van Poppel, Britt Stuge, Karim M Khan
Journal: British Journal of Sports Medicine (2017)

This is Part 4 in the series of reviews from the International Olympic Committee (IOC) expert committee on exercise and pregnancy in recreational and elite athletes. Part 1 focused on the effects of training during pregnancy and on the management of common pregnancy-related complaints experienced by athletes;1 Part 2 addressed maternal and foetal perinatal outcomes;2 Part 3 reviewed the implications of pregnancy and childbirth on return to exercise and on common illnesses and complaints in the postpartum period.3 Parts 1–3 are all open access papers. In Part 4, we recommend future research based on Parts 1–3. The systematic reviews, on which the previous Parts were based, revealed many gaps in knowledge relating to strenuous exercise during pregnancy and in the postpartum period, in both regular recreational exercisers and elite athletes. Important research questions are listed below, in relation to the foci of Parts 1–3, under the following headings: exercise during pregnancy, exercise related to birth outcomes and exercise in the postpartum period. References to existing research in the respective areas are listed in the previously Parts 1–3 and are not repeated here. ### Research questions related to exercise during pregnancy (based on the review of the effects of training during pregnancy and on the management of common pregnancy-related complaints experienced by recreational and elite athletes1).
Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE‐HF) study
Authors: Lars H. Lund, Jean‐Noel Trochu, Bart Meyns, Kadir Caliskan, Steven Shaw, Jan D. Schmitto, David Schibilsky, Laura Damme, Jerry Heatley, Finn Gustafsson
Journal: European Journal of Heart Failure (2017)